Botox for depression? No need for furrowed brows, says Allergan's head of R&D David Nicholson

16 January 2017
david-nicholson-large

Given that it is best known for its aesthetic potential in reducing facial wrinkles, few people will know that Botox (onabotulinumtoxinA) has as many as 11 separate therapeutic indications, treating conditions ranging from overactive bladder to chronic migraines.

Fewer people still will be aware that Botox is being investigated as a treatment for major depressive disorder (MDD), with early results suggesting that injecting the neurotoxic protein into the glabella area can have highly promising results even in patients with treatment-resistant depression.

What is clear is that Ireland-incorporated drugmaker Allergan (NYSE: AGN) is making the most of what it one of its flagship products, and that it is not finished there, as shown by its investigations in depression, an area of limited progress in recent decades.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical